Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Basal Insulin – GLP-1 receptor agonist combination therapy: convenience, compliance and overcoming clinical inertia

About the accreditation

HARDWARE AND SOFTWARE

The Insuline Educational Programme courses, which have been developed using HTML5 technologies, are accessible by using the following browsers:

Laptop/Desktop Version

IE9.0

IE10

IE11

Chrome
latest (version 48)

Safari latest

Firefox
latest

Win 7

Yes

Yes

Yes

Yes

Yes

Win 8.1

  

Yes

Yes

Yes

 -

Yes 

Mac 10.7x

 

 

 

-

Yes

 

Mac 10.8x

-

-

Yes

-

Certain activities may require additional software to view multimedia, presentations, or printable versions of the content. These activities will be marked as such and links will be provided to the required software. That software may include: Adobe Flash Player, Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.


ACCREDITATION STATEMENT

“Basal insulin – GLP-1 receptor agonist combination therapy: convenience, compliance and overcoming clinical inertia”, made available on “https://diabetes.elsevierresource.com/” and organized by “Elsevier”, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

“Basal insulin – GLP-1 receptor agonist combination therapy: convenience, compliance and overcoming clinical inertia””, made available on “https://diabetes.elsevierresource.com/” and organized by “Elsevier”, is awarded “1” European CME credits (ECMEC's).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.


CREDIT DESIGNATION STATEMENT

The UEMS-EACCME designates this educational activity for a maximum of 1.0 (1 Credit). Physicians should only claim credit commensurate with the extent of their participation in the activity.


DISCLOSURES AND CONFLICTS OF INTEREST
It is the policy of the UEMS-EACCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this e-CME activity discloses the following:

 

Faculty member and physician taking responsibility for content

 

Manufacturer

 

Relationship

Prof. Clifford J. Bailey

 

Advisory Boards: Astra Zeneca, BI/Lilly, Janssen, MSD, Novo Nordisk, Sanofi and several small biotech companies. 


I have attended and spoken at conferences and medical education events that have a variety of sponsors, including pharmaceutical companies

 

Consultant – Advisory Board

 

 

 

Speaker’s Bureau

Prof. Steve Bain

 

Novo Nordisk, Sanofi & Eli Lilly

 

Speaker’s Bureau

Prof. Stefano del Prato

 

MSD, Novartis Pharmaceutical Co., Novo Nordisk

Astra Zeneca, Boehringer Ingelheim, Eli Lilly & Co., GSK, Hanmi Pharmaceuticals, Intarcia, Janssen, MSD, Novartis, Novo Nordisk, Sanofi, Servier, Takeda

 

Grant/Research Support



Consultant

Prof. Kamlesh Khunti

 

Astra Zeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer-Ingelheim, MSD and Roche

Astra Zeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, MSD, Janssen, Boehringer Ingelheim

Astra Zeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, MSD, Janssen, Boehringer Ingelheim

 

Grant/Research Support





Consultant



 

Speaker’s Bureau

Prof. Francesc Xavier Cos Claramunt  

Novo Nordisk, Eli Lilly, Sanofi, Roche diagnostics, Boehringer Ingelheim

Novartis, Roche diagnostics, Astra Zeneca, Sanofi, Novo Nordisk, Boehringer Ingelheim

 

Consultant




Speaker’s Bureau

 

CONFLICT OF INTEREST STATEMENT

Elsevier has obtained the above signed faculty disclosures and has submitted these to the UEMS-EACCME to implement any process to resolve conflicts of interest for this CME activity. In order to help ensure that content of this course is objective, independent, fairly balanced, and aligned with the interest of the public.


UNAPPROVED/OFF-LABEL USE DISCLOSURE

The UEMS-EACCME requires CME faculty to disclose to the participants:

  • If products or procedures being discussed in a course are off-label, unlabeled, experimental, and/or investigational
  • Whether any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
  • That medical advisors, authors, speakers and/or moderators disclose when a product is not approved or not approved for the use under discussion.


INTENDED AUDIENCE

This activity has been developed for diabetes specialists. Due diligence and care have been taken when preparing module content to reflect the internationally recognized WHO, FDA, EMA terminologies. Furthermore, the module contents were drawn from a number of other countries worldwide, and the literature cited within the modules includes both European and global datasets, thus reflecting an international perspective on the topics. The content uses terminology fully consistent with the relevant peer-reviewed literature, and no country-specific brand names are used. It is therefore considered appropriate for an international audience.


PROGRAMME GOALS

After completing this module, participants will:

  • Understand the concept of clinical inertia
  • Know when to intensify treatment
  • Appreciate the rationale for combining basal insulin with a GLP-1 RA
  • Appreciate the convenience of basal insulin – GLP-1 RA combination, and understand how this combination could help overcome clinical inertia
  • Be able to identify patients for whom treatment with the basal insulin – GLP-1 RA combination would be a viable option
     

EDUCATIONAL OBJECTIVES

The educational needs will be achieved by systemically addressing the need for communication through:

      (a) Raising awareness on insulin management, to support physicians in recognizing practical implications, such as efficacy and safety.
      (b) Assessing the competency of the learner through a post-test evaluation after completion of the course.
      (c) Assessing the quality of the course by the learners through a post-course evaluation to be completed by the learner.


CME CREDIT INFORMATION

Release Date: 13 February 2017
Expiration Date: 13 February 2019
Accreditation: 1 hour


FINANCIAL SUPPORT

Disclosure of Financial Relationships:
Elsevier hereby discloses that the e-Learning Modules and Resource Center is sponsored by Novo Nordisk.

Statement of Purpose:
The Activity is for scientific and educational purposes only and will not promote Novo Nordisk’s products, directly or indirectly and is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence, or provide favourable formulary status for any of it’s products. The website is based upon a budget proposal provided to Novo Nordisk by Elsevier reflecting a good faith estimate of the actual cost of the educational or scientific Activity to be funded pursuant to this Letter of Agreement. The amount has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novo Nordisk and Elsevier or any of their respective officers, directors, employees, agents, affiliates, parents, or subsidiaries.

Control of Content:
Elsevier is responsible for control of content and selection of medical advisors, authors, presenters, and moderators (if any). Novo Nordisk will not “script,” target points for emphasis or control in any way the planning, content, author/speaker selection, or execution of any Activity that is funded.

Objectivity & Balance:
The Activity will be independent, non-promotional, and free from commercial influence or bias. If Novo Nordisk’s products are mentioned in the course of this Activity, Elsevier will make every effort to ensure that data regarding Novo Nordisk’s products (and competing products) are objectively selected and presented, with favourable and unfavourable information and balanced discussion of prevailing information on the product(s) and/or alternate treatments. The title of the Activity will fairly and accurately represent the scope of the presentation. The Activity will present discussion of multiple treatment options, and will not focus on a single product, except when options are so limited as to preclude meaningful discussion. Elsevier will ensure, to the extent possible, disclosure of limitations of data, e.g. ongoing research, interim analyses, preliminary data, or unsupported opinion.


USER PRIVACY AND CONFIDENTIALITY STATEMENT
Elsevier, being the developer and provider of this activity, respects and confirms the privacy and confidentiality of the Learner, and confirms that any information provided by the Learner will only be utilized for the specific purposes of completing the material.


RELEVANT ETHICAL, MEDICO-LEGAL, AND LEGAL REQUIREMENTS

Elsevier agrees to abide by all relevant standards including: (a) the governing accrediting body standards; (b) Union of European Medical Specialist guidelines; (c) any locally relevant Pharmaceutical Code; and (f) all other obligations under applicable mandatory legislation.

The course will be provided to the Learner, subject to Elsevier’s online Privacy Policy and its online general Terms and Conditions.

The disclaimer below shall be included in the Terms and Conditions which specifically relates to medical or health services information:

“If the Content contained on this site contains medical or health sciences information, it is intended for professional use within the medical field. No suggested test or procedure should be carried out unless, in the reader's judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that the independent verification of diagnoses and drug dosages should be made. Discussions, views, and recommendations as to medical procedures, products, choice of drugs, and drug dosages are the responsibility of the authors.”


HELP – ASSISTANCE

The course has a built in user help button to guide the learner through all relevant areas of the course.


CONTACT DETAILS FOR TECHNICAL OR OTHER ASSISTANCE

The Insulin Educational Programme have provided the email address of: elsevierpharmasolutions@elsevier.com

The learner/user may address all issues regarding the course and or website via this address which will be monitored 24 hours daily and responded to within 48–72 hours of the inquiry.


TO PRINT YOUR CERTIFICATE

The learner/user will be prompted and guided to the Insulin Programme modules for course evaluation feedback and a printable certificate.


DESCRIPTION OF PROVIDER

Elsevier is committed to making genuine contributions to the science and health communities. We are proud to be part of the science and health communities and to participate in the advancement of these fields. By delivering world-class information and innovative tools to researchers, students, educators, and practitioners worldwide, we help them become increasingly more productive in their work. We make substantial investments of capital and resources, which are required to manage the complex processes and innovations that serve the needs of the global science and health communities.


NAMES AND QUALIFICATIONS OF INDIVIDUALS RESPONSIBLE FOR PREPARATION OF CONTENT

Clifford J. Bailey, PhD, FRCP(Edin), FRCPath
Life and Health Sciences, Aston University.
Birmingham, UK

Steve Bain
Institute of Life Sciences Swansea University and Abertawe Bro
Swansea, UK

Stefano del Prato
University of Pisa
Pisa, Italy

Kamlesh Khunti
Leicester Diabetes Center
Leicester, UK

Francesc Xavier Cos
Catalonian Health Institute
Barcelona, Spain

Disclosure
The physicians taking responsibility for the content and the medical advisor were responsible for the medical content and received editorial/writing support in the preparation of this course. This course has been sponsored by Novo Nordisk.

Acknowledgment
Giorgio Sesti, MD, Professor of Internal Medicine, independent reviewer, University Magna Graecia of Catanzaro, Catanzaro, Italy
Dr. Adriana Stan, PhD, CMPP provided scientific writing/editorial support for this course

Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.


Search this site

Search form


 

Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk